[{"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin, Concord, Receive US FDA Approval for Mycophenolate Mofetil Tablets USP","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Lupin Ltd"},{"company":"Zydus Cadila","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cadila Pharmaceuticals Launches Cadalimab\u2122 (adalimumab Biosimilar) for India","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Zydus Cadila"},{"company":"Strides Arcolab Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Prednisone Tablets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Strides Arcolab Limited"},{"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Glenmark Pharmaceuticals"},{"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Glenmark Pharmaceuticals"},{"company":"Glenmark Pharmaceuticals","sponsor":"Menarini","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris\u2122 Nasal Spray in Europe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Glenmark Pharmaceuticals"},{"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Mycophenolate Mofetil Tablets USP","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Lupin Ltd"},{"company":"J.B.Chemicals & Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JB Chemicals Gets USFDA Nod for Generic Product","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"J.B.Chemicals & Pharmaceuticals"},{"company":"Strides Shasun Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Prednisone Tablets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Strides Shasun Limited"},{"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark\u2019s Ryaltris\u00ae- Innovative Single Nasal Spray Ready to Market in Russia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Glenmark Pharmaceuticals"},{"company":"Shilpa Medicare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shilpa Medicare Gets Tentative American Health Regulator Nod for Apremilast Tablets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Shilpa Medicare"},{"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark's Ryaltris Nasal Spray Now Approved in Europe for the First Line Treatment of Allergic Rhinitis in Patients over 12 Years of Age","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Glenmark Pharmaceuticals"},{"company":"Venus Remedies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venus Remedies wins legal battle against French firm for paracetamol patent","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Venus Remedies"},{"company":"Alkem Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkem Laboratories Launches Ibuprofen, Famotidine Tablets in US Market","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Alkem Laboratories"},{"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Gets Marketing Approval for Ryaltris in 13 EU, UK Countries","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Glenmark Pharmaceuticals"},{"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Generic Duexis Tablets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Lupin Ltd"},{"company":"Glenmark Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Specialty S.A. (Switzerland) Receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris\u2122 Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age and ","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Glenmark Pharmaceuticals"},{"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Launches Generic Methylprednisolone Sodium Succinate for Injection in US","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Dr. Reddy\\'s Laboratories"},{"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Posaconazole Delayed-Release Tablets in the U.S. Market","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Dr. Reddy\\'s Laboratories"}]
Details:
Launch of posaconazole delayed-release tablets, 100 mg, therapeutic generic equivalent to NOXAFIL® (posaconazole) delayed-release tablets, 100 mg approved by U.S.FDA, indicated for prophylaxis of invasive aspergillus and candida infections in patients.
Lead Product(s):
Posaconazole
Therapeutic Area: Immunology
Product Name: Posaconazole-Generic
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 20, 2022
Details:
Generic Methylprednisolone Sodium Succinate for injection, is the generic equivalent of Solumedrol, and has been approved by the U.S.FDA, indicated for various conditions including arthritis, blood disorders and severe allergic reactions.
Lead Product(s):
Methylprednisolone Sodium Succinate
Therapeutic Area: Immunology
Product Name: Methylprednisolone Sodium Succinate-Generic
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 06, 2022
Details:
Ryaltris (Olopatadine hydrochloride and mometasone furoate) is a metered, fixed-dose combination nasal spray used for the treatment of symptoms of Seasonal Allergic Rhinitis in adults and pediatric patients 12 years of age and older.
Lead Product(s):
Olopatadine Hydrochloride,Mometasone Furoate
Therapeutic Area: Immunology
Product Name: Ryaltris
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Hikma Pharmaceuticals
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 14, 2022
Details:
Ryaltris® (olopatadine 665 µg and mometasone furoate 25 µg), is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age.
Lead Product(s):
Olopatadine Hydrochloride,Mometasone Furoate
Therapeutic Area: Immunology
Product Name: Ryaltris
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 30, 2021
Details:
Global pharma major Lupin Limited announced the launch of the authorized generic version of Duexis (ibuprofen and famotidine) tablets, 800 mg/26.6 mg, of Horizon Medicines.
Lead Product(s):
Ibuprofen,Famotidine
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 15, 2021
Details:
Ibuprofen and Famotidine Tablets is AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis® Tablets, 800 mg/26.6 mg.
Lead Product(s):
Ibuprofen,Famotidine
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 04, 2021
Details:
Venus Remedies had initiated the legal battle in order to remove any patent hurdle in manufacturing of intravenous paracetamol solution in the country.
Lead Product(s):
Paracetamol
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 17, 2021
Details:
Glenmark will commercialise Ryaltris® on its own in select markets. In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark in 2020.
Lead Product(s):
Olopatadine Hydrochloride,Mometasone Furoate
Therapeutic Area: Immunology
Product Name: Ryaltris
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 26, 2021
Details:
The company has received tentative approval from US Food and Drug Administration for its abbreviated new drug application (ANDA) Apremilast tablets in the strengths of 10 mg, 20 mg, and 30 mg, Shilpa Medicare said in a regulatory filing.
Lead Product(s):
Apremilast
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 05, 2021
Details:
Ryaltris® (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg), is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age.
Lead Product(s):
Olopatadine Hydrochloride,Mometasone Furoate
Therapeutic Area: Immunology
Product Name: Ryaltris
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 22, 2021
Market Place
News Type
Offering a portfolio of products & services including APIs, CMO services, generics, biosimilars & differentiated formulations. 
